Comparing the current results to its competitors, Unity Biotechnology Inc reported Revenue decrease in the 1 quarter 2025 year on year by 0 %, slower than the combined decrease of the UBX's competitors by -6.58 %, recorded in the same quarter.
Unity Biotechnology Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 21.02 %
Unity Biotechnology Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, which is characterized by rapid technological and scientific changes and significant competition. Its drug candidates, if approved, will compete with products from larger pharmaceutical, biotechnology, and wellness companies, as well as academic research institutions, government agencies, and private institutions. Many competitors have substantially greater resources. The company faces risks related to potential patent infringement claims that could result in costly litigation and restrict commercialization. It intends to commercialize its products in the U.S. and other key markets through internal infrastructure or external partnerships.
April 23, 2024
UNITY Biotechnology Extends Phase 2b ASPIRE Clinical Study for UBX1325 in DME, Aiming to Enhance Durability and Statistical PowerSOUTH SAN FRANCISCO, Calif., April 23, 2024 - UNITY Biotechnology, Inc. (UNITY) NASDAQ: UBX, a prominent biotechnology company focused on developing innovative therapies to slow down, halt or even reverse diseases associated with aging, disclosed today the extension of its ongoing Phase 2b ASPIRE study of UBX1325. This extension will allow for an additional 12 weeks, totaling 36 weeks, to assess the potential for greater durability when compared to aflibercept. Simultaneously, the study has been upsized from 40 to 50 patients to bolster its statistical power. The primary of the AS...
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Pepgen Inc is a biotechnology company that operates on a business model focused on developing and commercializing transformative therapies for genetic diseases. They leverage their expertise in synthetic biology and gene editing technologies to create novel peptide-based therapies that can address previously untreatable genetic conditions. Pepgen Inc aims to partner with healthcare organizations and pharmaceutical companies to bring their innovative treatments to market.
Outlook Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing monoclonal antibody-based therapies for various ophthalmic indications. Their business model revolves around leveraging their expertise in developing cost-effective, innovative treatments that address unmet medical needs in the ophthalmic market.
Ocugen Inc's business model is focused on the development and commercialization of innovative gene therapies to treat rare and underserved ocular diseases, with a particular emphasis on underserved patient populations. They aim to leverage their expertise in gene therapy and partnerships to advance novel treatments and bring them to market, ultimately improving the lives of patients in need.
Sources:
Unity Biotechnology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Unity Biotechnology Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
